Source: Annual Congress 2004 - Fibrosing lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. R. Flaherty, M. Peters-Golden, W. Travis, T. Colby, B. Gross, E. Kazerooni, G. Toews, D. Dahlgren, F. J. Martinez (Ann Arbor, Washington, Scottsdale, United States Of America). Zileuton versus azathioprine/prednisone in idiopathic pulmonary fibrosis. Eur Respir J 2004; 24: Suppl. 48, 1673

Member's Comments

No comment yet.

Related content which might interest you: A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 High-dose acetylcysteine in idiopathic pulmonary fibrosis Source: ISSN=ISSN 1810-6838, ISBN=, page=358 Year: 2006 Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Colchicine, prednisone versus no therapy in idiopathic pulmonary fibosis Source: Eur Respir J 2006; 28: Suppl. 50, 744s Year: 2006 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Idiopathic pulmonary fibrosis and pirfenidone Source: Eur Respir J 2010; 35: 728-729 Year: 2010 Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017 Year: 2017 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016